# JSKN022 in Subjects With Advanced Malignant Solid Tumors

> **NCT07292402** · PHASE1 · RECRUITING · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 225 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **DRUG:** JSKN022

## Key facts

- **NCT ID:** NCT07292402
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-23
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07292402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07292402, "JSKN022 in Subjects With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07292402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*